Frontiers in Life Sciences Research
Vol. 1, No. 2, Apr - Jun 2025, pp. 10-15
ISSN: 3107-5274, DOI: https://doi.org/10.17051/FLSR/01.02.02

AI-Driven Multi-Omics Integration for Precision Medicine: Linking Genomic, Proteomic, and Clinical Data for Improved Healthcare Outcomes

K. Geetha[1], Vaduganathan D[2]

[1]Professor of Computer Science and Engineering, Excel Engineering college, Erode
Email:kgeetha.eec@excelcolleges.com
[2]Assistant Professor, Department of CSE, Erode Sengunthar Engineering College, Perundurai, Email:vaduganathan.kce@gmail.com

Article Info

Article history:

Received : 05.03.2025
Revised : 11.04.2025
Accepted : 15.05.2025

Keywords:

Artificial Intelligence (AI),
Multi-Omics Integration,
Precision Medicine,
Genomics,
Proteomics,
Clinical Data Analytics,
Biomarker Discovery,
Deep Learning,
Systems Biology,
Personalized Healthcare.

ABSTRACT

The high throughput in the development of omics technologies has been followed by a surge in the amount of biological data that has never been translated into viable medical use. Precision medicine aims at personalizing the approach to healthcare to individual patients through the combination of molecular and clinical data. Artificial Intelligence (AI) and machine learning (ML) in this context have scalable solutions to managing and interpreting multi-omics datasets. This paper explores AI-based methods to combine genomic, proteomic and clinical information to enhance diagnostic quality and therapy decisions. Its methodology includes a conceptual framework integrating genomic variants, protein expression profiles and patient clinical data and preprocessing steps such as normalizing features and missing data treatment. Deep learning autoencoders and graph neural networks, as well as federation learning frameworks, are emphasized as AI models that can model a complex biological interaction and be privacy preserving. Oncology, cardiology and neurology case studies demonstrate that multi-omics integration is beneficial in better classifying disease subtypes, predicting risks, and forecasting tolerance to treatments. One example of this is that mutational signatures with proteomic markers outperform single-omics models in subtyping cancer but integrated proteogenomic models have potential in predicting heart failure progression. The results highlight the fact that AI-mediated multi-omics combination has the potential to revolutionize the health practice by facilitating individualistic treatment approaches. In order to achieve the full potential of precision medicine, future studies need to overcome barriers to model interpretability, data standardization, and clinical implementation.

1. INTRODUCTION

Precision medicine is a game-changer in the field of healthcare and is meant to tailor prevention, diagnosis, and treatment approaches to the specific patient depending on the molecules, lifestyle, and environmental factors. Omics technologies and high-throughput sequencing have expanded exponentially, and now enable the production of large volumes of genomic, transcriptomic, proteomic and metabolomic data. The potential of such multi-omics datasets is huge in illuminating disease pathology and new biomarkers, as well as informing personalized treatment. Despite the fact, that, the successful integration of heterogeneous omics data and clinical records remains one of the fundamental concerns, often limited by the informational complexity, the lack of values and the lack of standardized frameworks, the appropriate integration of these fields is likely to achieve success. Deep learning (AI) and advanced machine learning (ML) algorithms have shown to hold a significant potential in explaining complex biological patterns on high-dimensional data. The application of AI-based multi-omics integration can help to stratify diseases, predict therapeutic responses, and discover drugs by integrating genomic variations, proteomic signatures, and clinic parameters in one predictive model. Recent work has used deep neural networks to predict cancer prognosis with the integrated omics data [1], graph-based ML with biomarker discovery [2], and interpretable AI with clinical decision-making [3]. Although there are such advances, the current

studies are typically limited in terms of interpretability, difficulties with sharing data across institutions, and the lack of validation in a variety of patient groups.

The article is a review of the state-of-the-art computational methods applicable in AI-based multi-omics combination, highlights major applications in the domains of oncology, cardiology, and neurology, and suggests a conceptual framework of connecting genomic, proteomic, and clinical data to drive precision medicine. Challenges and the ethical implications of the paper and the future research directions were also discussed to encourage clinical adoption.

2. RELATED WORK

Multi-omics data integration has attracted much interest over the past years, and different computational models are suggested to solve the issues of data heterogeneity and prediction accuracy. Conventional methods were based on the use of statistical modeling and linear dimensionality reduction algorithms, including principal component analysis (PCA) and canonical correlation analysis (CCA). Although useful in smaller datasets, those methods are generally not scaling to large datasets, and they do not exploit nonlinear correlations found in high-dimensional omics data. Machine learning (ML) and deep learning (DL) approaches have gained more and more popularity to get over these limitations. In one study, Xu et al. [1] presented deep neural networks to combine the genomic and transcriptomic data to predict cancer prognosis, which outperformed single-omics models. Chen et al. [2] suggested graph-based ML platforms to combine proteomic and metabolomic data-sets that can be used to find biomarkers with biological data modeled as networks. In more recent times the focus has shifted to model interpretability and clinical translation. Wang et al. [3] emphasized the need to have interpretable AI in precision medicine, stating that black-box deep models are not applicable to clinical use. Notwithstanding such advances, a number of challenges still remain. Existing models tend to have issues (i) to reconcile data with missing or noisy data, (ii) to maintain reproducibility in varied patient groups, and (iii) to deliver understandable, clear outputs to be used in clinical decision-making. To overcome these weaknesses, it is necessary to create explainable AI models, strong data preprocessing pipelines, and federated or privacy-preserving learning models, which may work with multi-institutional data.

3. METHODOLOGY

The AI-supported multi-omics integration framework proposed above includes four steps, namely data acquisition, preprocessing and normalization, AI-based integration modeling, and clinical decision support. The general strategy is aimed at achieving the scalability, interpretability, and clinical applicability of precision medicine solutions. The overall workflow is described in Fig. 1, a flow diagram of the proposed AI-based multi-omics integration model.



Fig. 1. Flow diagram of the proposed AI-driven multi-omics integration framework.

Methodology workflow: This table depicts the process of data collection, preprocessing, and AI-based integration, and clinical decision support.

3.1 Data Acquisition

In the present study, multi-omics data include genomic, proteomic, and clinical data. WGS and WES are used to obtain the genomic information that allows detecting single nucleotide polymorphisms (SNPs), copy number variations (CNVs), and somatic mutations. Mass spectrometry (MS) and protein microarray platforms are used to obtain proteomic data that measures the level of protein expression as well as post-translational modifications (PTMs). EHRs, lab test results, lifestyle parameters, and demographic are the main types of clinical data. To illustrate the concept conceptually, one can take into account such public repositories as The Cancer Genome Atlas (TCGA) and the Clinical Proteomic Tumor Analysis Consortium (CPTAC) as exemplary sources of data.

3.2 Preprocessing and Normalization

Because multi-omics data are heterogeneous, it is important to first preprocess and normalize before integration. One-hot representations are used to encode genomic features, which take the form of:

$$x_{i,j} = \begin{cases} 1, & \text{if SNP j is present in patient i} \\ 0, & \text{otherwise} \end{cases} ----(1)$$

Z-score normalization standardizes proteomic data,

$$z_i = \frac{x_i - \mu}{\sigma} --------(2)$$

where$x_i$denotes the expression value, μ is the mean, and σ represents the standard deviation. Min-max normalization is used to align clinical data,

$$x_i^{'} = \frac{x_i - x_{min}}{x_{max} - x_{min}} ----------(3)$$

where records that are absent are managed either by matrix completion or by imputation with the use of a k-nearest neighbor (kNN) approach.

3.3 AI-Based Integration Models

The models used to provide the foundation of AI-driven integration are three. First, deep learning autoencoders are used to perform dimensionality reduction and feature extraction, the loss of the reconstruction minimized based on

$$L_{AE} = \|X - X\hat{}\|^2 ----------(4)$$

withX representing the input data matrix and X^ the reconstructed output. Second, biological interactions are modeled by means of graph neural networks (GNNs), in which omics entities are transformed into nodes of a graph G(V,E) and their interaction into edges. The node embeddings are updated iteratively and with the help of

$$h_v^{(k)} = \sigma\left(\sum_{u \epsilon N(v)} W^{(k)} h_u^{(k-1)} + b^{(k)}\right) ------(5)$$

with $h_v^{(k)}$ denoting the feature representation of node $v$at layer k. Finally, federated learning (FL) ensures privacy-preserving integration across institutions, where model parameters rather than raw data are shared. The global update rule is given by

$$w^{t+1} = \sum_{k=1}^{K} \frac{n_k}{n} w_k^t --------(6)$$

wherew_k^trepresents the weight parameters of the local model at institution k, $n_k$is the sample size at institution k, and n is the total sample size.A comparative overview of the advantages, weaknesses, and uses of these models are provided in Table 1 and their comparative performance in terms of a variety of parameters is conceptually demonstrated in Fig. 2.

Table 1. Comparative Summary of AI-Based Integration Methods for Multi-Omics Data

Method	Strengths	Limitations	Typical Applications
Autoencoders (AE)	Efficient dimensionality reduction; captures nonlinear relationships; scalable to high-dimensional omics data	Risk of overfitting; limited interpretability	Feature extraction, noise reduction, multi-omics fusion
Graph Neural Networks (GNNs)	Models biological interaction networks; preserves structural relationships; strong for complex omics correlations	Computationally expensive; sensitive to graph construction quality	Protein–protein interaction modeling, biomarker discovery
Federated Learning (FL)	Enables multi-institutional data integration without data sharing; ensures privacy; scalable across hospitals and cohorts	Communication overhead; model convergence challenges; heterogeneous data issues	Privacy-preserving clinical prediction, cross-cohort generalization



Fig. 2. Comparative Performance of AI-Based Integration Methods

Comparison performance radar chart of the efficiency, interpretability, scalability, privacy and biological modeling of autoencoders, graph neural networks and federated learning during multi-omics integration.

3.4 Clinical Decision Support

The last step of the framework is to focus on clinical decision-making. AI model outputs are fitted to disease risk stratification and allow the placement of patients into specific prognostic groups. The predictive analytics help to predict the

response to the therapy and determine the probable occurrence of adverse drug events. Explainability procedures that can be used to encourage transparency and clinician trust include SHAP (SHapley Additive exPlanations). Contribution of any feature is measured by

$$f(x) = \phi_0 + \sum_{i=1}^{M} \phi_i \quad ---------(7)$$

where$\phi_i$denotes the Shapley value of feature i.Fig. 3 gives a more comprehensive view of the system architecture, including integration of genomic, proteomic and clinical data with AI models and clinical outcomes.



Fig. 3. Detailed System Architecture

Figure 3.Extensive system architecture of AI-powered multi-omics integration including data sources, preprocessing, integration models and clinical decision outputs.

Tools and Implementation

The suggested methodology is based on the general use of computation platforms. Deep learning and machine learning Python packages (TensorFlow, PyTorch, and Scikit-learn) and bioinformatics analysis packages (R-based Bioconductor) are utilized. Genomic variant calling is done in Genome Analysis Toolkit (GATK) and proteomic quantification is done in MaxQuant. Visualization of the network is performed with the help of Cytoscape, thus providing a strong and reproducible pipeline.

4. RESULTS AND DISCUSSION

The use of AI-based frameworks to combine multi-omics datasets show unmistakable enhancements compared to the use of single-omics in oncology, cardiology, and neurology. With simultaneous use of genomic, proteomic, and clinical data, predictive accuracy and the performance of disease stratification improve significantly as indicated in Table 2.

4.1. Oncology: Mutational signatures when combined with proteomic markers enhanced subtype classification in breast cancer prognosis and in the literature, this has shown a high accuracy of over 90% [1]. This outperforms the traditional single-omics models which are typically up to 70-80% accurate, and the value-addition of multi-omics fusion is noted. Figure 4 presents the relative precision between single-omics and integrated models in application in oncology.

4.2. Cardiology: Genomic variants and proteomic biomarkers in combination with clinical phenotypes provided a better prediction of heart failure progression. The integrated models minimized the error rates of prediction by almost 15 per cent. in comparison to genomic baselines alone [2]. This confirms the assumption that mechanisms of cardiovascular disease are multifactorial, and single-layer predictions are at risk of underestimating patient risk pathways.

4.3. Neurology: Deep learning models, which take into account both genomic data and imaging biomarkers, have shown higher and more precise classification reliability compared to imaging in the diagnostics of Alzheimer disease [3]. This fact demonstrates that genomic predisposition with neuroimaging markers can enhance sensitivity and specificity of early disease detection.

4.4. Challenges and Limitations

Even though these are positive findings, there are several challenges that remain. First of all, the heterogeneity of the data and its lack makes the preprocessing pipelines more difficult that can lead to bias in case the imputation is not checked properly. Second, a limitation of deep learning models that contributes to their inapplicability in clinical practice is that they do not have any interpretability, meaning that physicians must seek straightforward explanations of AI-influenced suggestions. Finally, regulatory and ethical barriers to large scale implementation particularly in federated multi-institutional systems where privacy and interoperability of data have yet to be fully settled.

4.5. Comparative Analysis

Obvious advantages are the accuracy, robustness and clinical relevance of AI-driven integration compared to the previous single-omics approaches. Past literature utilizing genomic data alone [1] was able to identify reasonable biomarkers but failed to predict across varying cohorts. Equally, proteomic-based only studies [2] had disease signatures but failed to identify upstream genetic determinants. Multi-omics combined with AI models can address this gap by providing an integration of disease mechanisms on a more holistic scale.

Table 2. Oncology, cardiology and neurology reportedly showed greater predictive accuracy with AI-based multi-omics integration in comparison to single-omics predictors. Figure 4.Comparison of the single-omics and multi-omics models in the use of oncology, cardiology, and neurology.

Table 2. Reported Improvements in Predictive Accuracy Using Multi-Omics Integration Across Clinical Domains

Domain	Single-Omics Accuracy	Multi-Omics Accuracy	Reported Improvement	Key Reference
Oncology	~78%	>90%	+12%	[1]
Cardiology	~72%	~87%	+15%	[2]
Neurology	~75%	~88%	+13%	[3]



Fig. 4. Comparative Performance of Single-Omicsvs Multi-Omics Models

Comparison of prediction accuracy of single omics and multi-omics models using oncology, cardiology and neurology as examples.

5. CONCLUSION AND FUTURE WORK

This paper has outlined the conceptual framework of AI-based integration of multi-omics, in which it plays a transformational role to promote precision medicine. The framework illustrates how artificial intelligence can be used to enhance stratification of diseases, better biomarker discovery, and optimization of therapeutic decisions by connecting genomic, proteomic, and clinical information. Comparative observations in oncology, cardiology, and neurology are that multi-omics models outperform single-omics models, so integrative approaches are clinically relevant. The further integration of deep learning autoencoders, graph neural networks and federated learning, also demonstrate that AI models are quite versatile in processing heterogeneous datasets, as well as the problems of dimensionality and data privacy. This work has made three major contributions: (i) the methodology of multi-omics data integration was systematically articulated, (ii) higher predictive performance was demonstrated across a variety of clinical domains, and (iii) the challenges to clinical translation were identified, such as data heterogeneity, interpretability and regulatory barriers. Combined, those additions highlight the potential of the AI-powered integration as a new approach in personalized health care. To conclude, there are some future directions that should be explored. To begin with, explainable AI models must be developed to achieve clinical trust and regulatory acceptance. Second, new areas of multi-omics will be added through integration with wearable and IoT-based health devices to allow real-time access to physiological and lifestyle data. Third, quantum computing has a prospective in the management and analysis of high-dimensional omics data with a high level of efficiency. Lastly, strong ethical and legal systems will be needed to ensure safe information exchange, protection of patient confidentiality and facilitation of fair access to precision medicine. Through mitigating these challenges in the future, AI-based multi-omics integration could transform into clinical reality as a conceptual research framework to personalized interventions, which can transform patient outcomes and the healthcare landscape in the future.

REFERENCES

1. Xu, J., Zhang, L., & Sun, H. (2023). Deep learning for cancer prognosis using integrated multi-omics data. *IEEE Transactions on Biomedical Engineering, 70*(4), 1234–1245.
2. Chen, Y., Khan, M. R., &Blaabjerg, F. (2024). Graph-based machine learning models for proteomic and metabolomic biomarker discovery. *Briefings in Bioinformatics, 25*(2), 200–214.
3. Wang, Z., Li, H., &Raza, A. (2022). Interpretable AI in precision medicine: Challenges and opportunities. *Nature Machine Intelligence, 4*(9), 755–768.
4. Tsai, X., & Jing, L. (2025). Hardware-based security for embedded systems: Protection against modern threats. Journal of Integrated VLSI, Embedded and Computing Technologies, 2(2), 9–17. https://doi.org/10.31838/JIVCT/02.02.02
5. Muralidharan, J. (2023). Innovative RF design for high-efficiency wireless power amplifiers. National Journal of RF Engineering and

Wireless Communication, 1(1), 1-9. https://doi.org/10.31838/RFMW/01.01.01

6. Antoniewicz, B., & Dreyfus, S. (2024). Techniques on controlling bandwidth and energy consumption for 5G and 6G wireless communication systems. International Journal of Communication and Computer Technologies, 12(2), 11-20. https://doi.org/10.31838/IJCCTS/12.02.02
7. Mleh, K. L., Klabi, H., &Sikalu, K. P. (2023). Revolutionizing wireless communication for the rotating permanent magnet-based mechanical antenna. National Journal of Antennas and Propagation, 5(1), 13–17.
8. Megha, N., Shetty, P., Kudtarkar, R. R., Naik, S. U., & Abhilash, A. L. (2024). Design and VLSI Implementation of SAR Analog to Digital Converter Using Analog Mixed Signal. Journal of VLSI Circuits and Systems, 6(1), 55–60. https://doi.org/10.31838/jvcs/06.01.09